FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
FibroBiologics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$0.94−0.03 (-2.77%)
Close on Oct 19, 2026
- Market cap
- $5.92M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
4.3%
0M of 7M shares
Institutional holders
16
3 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $120.49K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven Boyd | 738,977 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Pete O'Heeron | 6,951,459 | 18.20% | 13G (passive) | Jan 31, 2024 |
| Hamid Khoja | 630,009 | 7.50% | 13D (active) | Sep 15, 2026 |
| Mike Newlin | 2,134,853 | 5.58% | 13G (passive) | Aug 9, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FBLG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cascade Financial Partners, LLC | 108,828 | 1.63% | $103.14K | +92,400 | 0.01% |
| Fund Evaluation Group, LLC | 51,794 | 0.78% | $49.09K | – | 0.00% |
| Geode Capital Management, LLC | 30,299 | 0.46% | $28.72K | +690 | 0.00% |
| Vanguard Capital Management LLC | 27,769 | 0.42% | $26.33K | −39,896 | 0.00% |
| Qube Research & Technologies Ltd | 24,313 | 0.37% | $23.04K | New | 0.00% |
| BlackRock, Inc. | 18,238 | 0.27% | $17.28K | −6,409 | 0.00% |
| Barclays PLC | 7,243 | 0.11% | $6.86K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 6,380 | 0.10% | $6.05K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 4,728 | 0.07% | $4.48K | +4,268 | 0.00% |
| Osaic Holdings, Inc. | 2,404 | 0.04% | $2.28K | +2,250 | 0.00% |
| Royal Bank of Canada | 1,522 | 0.02% | $1.00K | +1,336 | 0.00% |
| UBS Group AG | 1,073 | 0.02% | $1.02K | −4,648 | 0.00% |
| Islay Capital Management, LLC | 169 | 0.00% | $160 | – | 0.00% |
| Grove Bank & Trust | 100 | 0.00% | $95 | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 64 | 0.00% | $61 | −2 | 0.00% |
| Allworth Financial LP | 13 | 0.00% | $13 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 16 | 0M | 4.3% | 3 / 5 | 4 / 4 | 0M | 0M |
| Q1 2026 | 17 | 0M | 3.3% | 17 / 0 | 0 / 0 | 0M | 0M |
| Q3 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FBLG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 27,769 | 0.42% | $26.32K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 19,544 | 0.29% | $22.67K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 2,571 | 0.04% | $2.98K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,266 | 0.03% | $2.63K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,099 | 0.02% | $1.27K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pete O'Heeron | CHIEF EXECUTIVE OFFICER, Director | 5,958,147 | 89.49% | May 4, 2026 |
| Hamid Khoja | Chief Scientific Officer | 301,571 | 4.53% | Sep 15, 2026 |
| Jason Davis | Chief Financial Officer | 70,000 | 1.05% | May 4, 2026 |
| Ruben A. Garcia | General Counsel | 180,000 | 2.70% | May 4, 2026 |
| Leigh Steinberg | Director | – | – | Sep 1, 2026 |
| Kathleen Hallisey Rubins | Director | – | – | Jul 16, 2026 |
| Matthew Link | Director | 7,500 | 0.11% | Jun 23, 2026 |
| Victoria Ninon Olivia Niklas | Director | 7,500 | 0.11% | Jun 23, 2026 |
| Robert E. Hoffman | Director | 7,500 | 0.11% | Jun 23, 2026 |
| Richard C. Cilento Jr. | Director | 93,225 | 1.40% | Jun 23, 2026 |
| Stacy Ann Coen | Director | 7,500 | 0.11% | Jun 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hamid Khoja Chief Scientific Officer | Sep 15, 2026 | Award | +298,508 | $1.68 | $501.49K | 301,571 |
| Hamid Khoja Chief Scientific Officer | Mar 4, 2026 | Buy | +30,000 | $0.38 | $11.40K | 61,250 |
| Pete O'Heeron CHIEF EXECUTIVE OFFICER, Director | Mar 4, 2026 | Buy | +15,872 | $0.38 | $6.03K | 5,958,147 |
| Pete O'Heeron CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2026 | Buy | +18,200 | $0.41 | $7.46K | 5,942,275 |
| Pete O'Heeron CHIEF EXECUTIVE OFFICER, Director | Mar 2, 2026 | Buy | +17,428 | $0.35 | $6.10K | 5,924,075 |
| Jason Davis Chief Financial Officer | Mar 2, 2026 | Buy | +70,000 | $0.41 | $28.70K | 70,000 |
| Ruben A. Garcia General Counsel | Feb 27, 2026 | Buy | +40,000 | $0.33 | $13.20K | 180,000 |
| Ruben A. Garcia General Counsel | Dec 11, 2025 | Buy | +140,000 | $0.34 | $47.60K | 140,000 |
| Hamid Khoja Chief Scientific Officer | May 27, 2025 | Buy | +20,000 | $0.84 | $16.80K | 31,250 |
| Pete O'Heeron Chief Executive Officer, Director | Dec 9, 2024 | Gift | −100,000 | – | – | 5,906,647 |
| Pete O'Heeron Chief Executive Officer, Director | Dec 3, 2024 | Gift | −50,000 | – | – | 6,006,647 |
| Pete O'Heeron Chief Executive Officer, Director | Aug 12, 2024 | Buy | +8,500 | $1.91 | $16.24K | 6,056,647 |
| Hamid Khoja Chief Scientific Officer | Aug 12, 2024 | Buy | +10,000 | $1.90 | $19.00K | 11,250 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.